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Abstract
OBJECTIVE—To test how genomic loci identified in genome-wide association studies (GWAS)
influence the developmental progression of smoking behavior.
DESIGN—A 38-year prospective longitudinal study of a representative birth-cohort.
SETTING—The Dunedin Multidisciplinary Health and Development Study, New Zealand.
PARTICIPANTS—N=1037 male and female study members.
MAIN EXPOSURES—We assessed genetic risk with a multi-locus genetic risk score (GRS).
The GRS was composed of single-nucleotide polymorphisms identified in three meta-analyses of
GWAS of smoking quantity phenotypes.
OUTCOME MEASURES—Smoking initiation, conversion to daily smoking, progression to
heavy smoking, nicotine dependence (Fagerstrom Test of Nicotine Dependence), and cessation
difficulties were evaluated at eight assessments spanning ages 11-38 years.
RESULTS—Genetic risk score was unrelated to smoking initiation. However, individuals at
higher genetic risk were more likely to convert to daily smoking as teenagers, progressed more
rapidly from smoking initiation to heavy smoking, persisted longer in smoking heavily, developed
nicotine dependence more frequently, were more reliant on smoking to cope with stress, and were
more likely to fail in their cessation attempts. Further analysis revealed that two adolescent
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developmental phenotypes—early conversion to daily smoking and rapid progression to heavy
smoking--mediated associations between the genetic risk score and mature phenotypes of
persistent heavy smoking, nicotine dependence, and cessation failure. The genetic risk score
predicted smoking risk over and above family history.
CONCLUSIONS—Initiatives that disrupt the developmental progression of smoking behavior
among adolescents may mitigate genetic risks for developing adult smoking problems. Future
genetic research may maximize discovery potential by focusing on smoking behavior soon after
smoking initiation and by studying young smokers.
INTRODUCTION
Cigarette smoking is a costly, prevalent public health problem. The US Centers for Disease
Control and Prevention attribute 400,000+ deaths and $95 million in lost productivity to
smoking during 2000-2004.1 About 20% of adults still smoke daily despite widespread
knowledge of smoking's health effects and increasing economic costs to smokers due to
rising taxes.2 Thus, more effective interventions to prevent smoking, motivate smoking
cessation, and prevent relapse back to smoking are needed.3-5
Studies of twins suggest that genetic differences between individuals play an important role
in smoking behavior, cessation, and in response to anti-smoking interventions.6 Recent
genome-wide association studies (GWAS) in adult smokers and former smokers revealed
genes that relate with genome-wide significance to smoking quantity (number of cigarettes
smoked per day).7-9 These genes are already being used in clinical applications; e.g., to
predict smoking cessation likelihood and in pharmacogenetic analyses.10-14 An important
additional step in the translation of these GWAS findings is to test if genetic markers that
predicted smoking quantity in GWAS also predict the development of smoking behavior in
adolescence.15,16 This question is of critical importance for public health practice as
intervention to disrupt genetic risk is likely to be most effective early in the development of
dependence. Important developmental phenotypes in the pathogenesis of adult dependence
include smoking initiation, conversion to daily smoking during adolescence, and rapid
progression to heavy smoking.17 Early, rapid progression from smoking initiation to heavy
use is a signal risk for adult nicotine dependence.18-21 Therefore, the present study tested
relations of GWAS-identified genetic risk with both adolescent and adult smoking
phenotypes and then determined the extent to which genetic effects on the former affected
the adult phenotype outcomes.
In this study, we tested prospective associations between genetic risks and adolescent
developmental and mature adult phenotypes of smoking behavior (Figure 1). We examined
genetic risks in the Dunedin Study, a birth cohort (n=1,037) followed to age 38 years with
>90% retention. We collected smoking behavior data at 8 assessments spanning ages 11-38
years. This allowed us to study the effects of genetic risk in the cohort as members initiated
smoking during adolescence, converted to daily smoking and progressed to heavy smoking
during the teenage and young adult years, and as they developed nicotine dependence and
struggled with cessation in their 20s and 30s. We tested whether individuals at higher
genetic risk progressed more rapidly from smoking initiation to heavy smoking, if they
smoked more heavily as adults, if they were more nicotine dependent, and if they were more
likely to fail in their cessation attempts. Finally, we tested the hypothesis that genetic risk
accelerates the developmental progression from smoking initiation to heavy smoking, and
this, in turn, increases the severity of adult smoking problems such as heavy, intractable
smoking and nicotine dependence. This model has relevance to public-health interventions
that might delay the developmental progression to heavy smoking. To put the magnitudes of
genetic risk effects in context and to determine whether molecular genetic measurements
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provided novel information about risk, we conducted an additional analysis comparing
molecular genetic information to family history information. These analyses asked how
large molecular genetic effects were relative to family history effects and whether molecular
genetic effects were independent of family history effects in predicting risk.
METHODS
Sample
Participants are members of the Dunedin Multidisciplinary Health and Development Study,
a longitudinal investigation of health and behavior in a complete birth cohort. Study
members (N=1,037; 91% of eligible births; 52% male) were all individuals born between
April 1972 and March 1973 in Dunedin, New Zealand, who were eligible for the
longitudinal study based on residence in the province at age 3 and who participated in the
first follow-up assessment at age 3. The cohort represents the full range of socioeconomic
status in the general population of New Zealand's South Island and is primarily white.22
Assessments were carried out at birth and at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and,
most recently, 38 years, when 1,004 Study members were still alive, with over 95%
retention. At each assessment wave, study members are brought to the Dunedin research unit
for a full day of interviews and examinations. The Otago Ethics Committee approved each
phase of the study and informed consent was obtained from all study members.
Measures
Genetic Risk Score—A challenge for developmental research following-up GWAS
discoveries is that effect sizes for individual single-nucleotide polymorphisms (SNPs) are
small; the largest effects for smoking quantity approach a change of 1 cigarette per day per
risk allele. Moreover, many of the longitudinal studies with data necessary to investigate
developmental phenotypes are underpowered to test single-SNP effects.23 However, there is
evidence that smoking-associated loci make additive contributions to risk, recommending
aggregating risk alleles.24-27 Summing risk alleles across GWAS-identified SNPs to
compute a “genetic risk score” (GRS) yields a quantitative index of genetic risk with a
normal distribution28 and a potentially larger effect size.
We derived the genetic risk score (GRS) from 3 recent meta-analyses of GWAS that used as
their phenotype cigarettes smoked per day.7-9 To construct the genetic risk score (GRS), we
considered single-nucleotide polymorphisms (SNPs) from regions with genome-wide
significant associations in at least two meta-analyses: All 3 meta-analyses identified SNPs in
the q25.1 region of chromosome 15 containing the CHRNA5-CHRNA3-CHRNB4 gene
cluster. Two meta-analyses identified SNPs in the q13.2 region of chromosome 19
containing the gene CYP2A6. These genes influence nicotine response and nicotine
metabolism, have been linked with nicotine dependence, and are candidate genes in research
into the development of smoking behavior.26,29-35 Therefore, we focused our inquiry on the
top GWAS SNPs in these two regions (Supplemental Methods). In 15q25.1, we selected
the SNPs rs16969968, rs6495308, rs8032771, and rs12595538. The SNPs rs16969968 and
rs6495308, which fall within the CHRNA5-CHRNA3-CHRNB4 gene cluster, were shown
previously to have independent associations with smoking quantity8 (see also36). The SNPs
rs8032771 and rs12595538, which are located downstream of the CHRNA5-CHRNA3-
CHRNB4 gene cluster, were in weak linkage-disequilibrium (LD) with rs16969968 and
rs6495308 (R2≤0.10), and were genome-wide significant in the largest meta-analysis7
(p<1×10-16 for both; p-values for these SNPs were not published in the other two meta-
analyses). In 19q13.2, we selected the SNPs rs7937 and rs4105144. Following two previous
studies using multi-locus measures of genetic risk for smoking, we assumed an additive
model and summed alleles associated with higher smoking quantity to calculate the
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GRS.25,27 Because no reference data exist to determine the exact contributions of individual
SNPs in our GRS to developmental phenotypes of smoking behavior, we used un-weighted
counts of risk alleles to construct the score.
To validate this GRS, we used independent data from the Atherosclerosis Risk in the
Communities (ARIC) database37 and the Study of Addiction: Genetics and Environment
(SAGE) database, accessed through the NIH database of Genotypes and Phenotypes
(dbGaP).38 When a GRS SNP was not available in one of these databases, we selected the
closest LD proxy for that SNP to include in the GRS. Among European-descent ARIC
participants (n=8,293), each standard deviation (SD) increase in the GRS predicted a 1.45
pack-year increase in lifetime cigarette consumption among individuals who had ever
smoked (p<0.001) and a 1.02 cigarette increase in daily consumption among these ever
smokers (p<0.001). Replication of the GRS-smoking quantity association in the SAGE
database and additional validation analyses testing versions of the GRS that exclude the
SNPs rs16969968 and rs6495308 are presented in Supplemental Table 2.
Dunedin cohort genotyping was conducted with a commercially available array (BeadPlex
Array; Illumina Inc.) using DNA extracted from whole blood (93% of the sample) or buccal
swabs (7% of the sample). GRS SNPs or proxies (linkage R2≥0.85) were called successfully
in >95% of European-descent study members (Supplemental Table 1). These n=880
individuals formed the analysis sample. Cohort members carried an average of 7.06 of 12
possible risk alleles (SD=2.27). Cohort members’ sex and socioeconomic status39 were
unrelated to their genetic risk (Pearson's r ≤0.01). The GRS was standardized to have
mean=0 and standard deviation=1 for analyses (genetic risk Z-score).
Family History of Smoking—Family histories of smoking were available for 99% of the
cohort. The family history consisted of reports of smoking history provided by study
members and both parents for study members’ siblings, parents, and grandparents. The
family history was summarized as the proportion of family members in the pedigree who
were ever regular smokers, adjusted to account for differences in genetic relatedness to the
proband of first- and second-degree relatives.40
Smoking Behavior—The developmental progression of smoking behavior in the Dunedin
cohort is described in Figure 2 Panel A. Measurement of adolescent developmental
phenotypes and mature phenotypes of smoking behavior is described in Figure 2 Panel B.
Analyses
Data analysis was divided into three parts: First, we analyzed associations between the GRS
and developmental phenotypes of smoking behavior. Second, we analyzed associations
between the GRS and mature phenotypes. Third, we tested whether developmental
phenotypes mediated associations between the GRS and mature phenotypes. We used
different statistical models to analyze outcome data as required by the outcome's
distribution. We analyzed continuously distributed outcome data (e.g. lifetime cigarette
consumption in pack years) using ordinary least squares (OLS). We analyzed dichotomous
outcome data (e.g. daily smoker by age 15 years) using Poisson regression models as this is
a standard method to derive relative risks.41 We analyzed count outcome data (e.g. the
number of assessments at which the study member met criteria for nicotine dependence)
using negative binomial regression models to account for the over-dispersion of many of the
count measures.42 We analyzed hazards of smoking initiation, progression to heavy
smoking, becoming nicotine dependent, and relapsing from a quit attempt using Cox
proportional hazard models. To account for differences in the frequency with which study
members attempted cessation, we constructed panel datasets that included one observation
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per study member per assessment (for the age 18-32 data) and one observation per study
member per quit attempt (for the life-history calendar data). We used these panel datasets to
analyze the genetic effect on smokers’ risks of cessation failure during ages 18-32 years and
on their hazards of relapse during ages 32-38 years. We accounted for non-independence of
repeated observations of individuals using generalized estimating equation models of risks
and conditional risk-set models of hazards.43,44 We tested whether genetic effects on the
mature phenotypes of persistent heavy smoking, nicotine dependence, and relapse were
mediated by adolescent developmental phenotypes using the structural equation described
by McKinnon and Dwyer and the methods described by Preacher and colleagues.45-47 In
order to allow for a single test of mediation, we conducted a principal components
analysis48 of the mature phenotypes of persistent heavy smoking (pack years smoked at age
38 years), nicotine dependence (total number of symptoms across all assessments), and
cessation failure (number of assessments with relapse). This analysis indicated that the
mature phenotypes were positively and significantly correlated (Supplemental Table 3) and
could be summarized in a single component that explained 78% of the variance in the three
measures (factor loading for persistent heavy smoking=0.61; for nicotine dependence=0.60;
for cessation failure=0.52). We used this component as the dependent variable in our
mediation analysis. Analyses were adjusted for sex and conducted using Stata 11.0.49 Panel-
data models were fitted to longitudinal repeated-measures data using “XT” and “ST”
commands in Stata 11.0. Unless otherwise noted, effect-sizes are presented for one-unit
increases in the genetic-risk Z-score (GRS).
RESULTS
Genetic risk was not related to smoking initiation
The GRS was not associated with whether individuals initiated smoking or with the timing
of initiation (relative risk (RR) for smoking initiation=0.98, 95% CI [0.95-1.02], cumulative
hazard ratio (HR) for initiation=1.01, [0.94-1.09] based on a one-unit increase in GRS z-
score, Table 1). Subsequent analyses focused on the 627 Dunedin cohort members who
initiated smoking at some point during follow-up (Figure 2).
Genetic risk was related to the progression of smoking behavior
Individuals at higher genetic risk were more likely to progress to smoking ≥20 cigarettes/day
and did so more rapidly (HR=1.35 [1.14-1.58]). Figure 3 Panel A shows the cumulative
hazards for smoking ≥20 cigarettes/day for individuals at low, average, and high genetic
risk. An unexpected finding was that individuals who initiated smoking but who did not
progress to daily smoking or to heavy smoking, so-called “chippers”, were at the lowest
genetic risk of any group in the cohort (Figure 3 Panel B).
Adolescents at higher genetic risk were more likely to convert to daily smoking early and
to progress rapidly from initiation to smoking ≥20 cigarettes/day
Among ever-smokers, 19% converted to daily smoking by age 15 years (early conversion)
and 10% progressed to smoking ≥20 cigarettes/day by age 18 years (rapid progression to
heavy smoking). Each unit increase in the GRS predicted a 24% increase in the relative risk
of early conversion (RR=1.24 [1.06-1.45]) and a 43% increase in the relative risk of rapid
progression (RR=1.43 [1.10-1.86]).
Individuals at higher genetic risk smoked more heavily across the lifespan
Individuals at higher genetic risk accumulated more pack-years across 38 years of follow-
up. Results from an OLS model indicated that each one-unit increase in the GRS predicted
an additional pack-year in lifetime cigarette consumption among ever-smokers (B=1.05
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[0.36-1.73]) (Figure 4 Panel A). We also analyzed the persistence of heavy smoking as the
number of assessments at which individuals smoked ≥20 cigarettes per day. Individuals at
higher genetic risk smoked heavily at more assessments (incidence rate ratio (IRR) for
number of assessments as a heavy smoker=1.26 [1.07-1.49]).
Smokers at higher genetic risk were more likely to develop nicotine dependence
Through age 38 years, 27% of ever-smokers developed nicotine dependence. Individuals at
higher genetic risk were more likely to become nicotine dependent compared to individuals
at lower genetic risk and were nicotine dependent at more assessments (HR for nicotine
dependence =1.27 [1.09-1.47]; IRR for assessments with nicotine dependence=1.22
[1.06-1.41]) (Figure 4 Panel B).
Smokers at higher genetic risk were more reliant on smoking as a coping strategy
In addition to testing genetic associations with nicotine dependence, we also asked whether
cohort members at higher genetic risk were more reliant on smoking to co pe with stress.
Among study members who smoked daily during ages 32-38 years (n=277), those at higher
genetic risk relied more heavily on smoking as a coping strategy (B=0.22 [0.11-0.32]).
Smokers at higher genetic risk were more likely to experience cessation failure
Assessment of cessation failure is challenging.50 Therefore, we looked for convergent
evidence across two approaches to testing genetic associations with cessation failure. We
first analyzed study members’ reports of cessation failure between ages 18-32 years. Across
14 years of follow-up, n=405 cohort members smoked daily. 90% of this group made at least
one quit attempt and 51% reported a cessation failure at one or more assessments. Cohort
members at higher genetic risk were more likely to experience cessation failure in their quit
attempts (RR=1.11 [1.01-1.22]).
We next used the month-to-month life history calendars to look closely at cohort members’
smoking behavior during their 30s, when cessation was most common. Across 72 months of
follow-up, n=277 cohort members smoked daily. 53% of these smokers made a quit attempt
lasting one month or more. Relapse was common (occurring in 62% of quitters). Quitters at
higher genetic risk were more likely to relapse and did so sooner after quitting (HR=1.22
[1.02-1.45]). Only 20% of daily smokers achieved successful cessation (abstinent for ≥1
year through age 38). Smokers at higher genetic risk were less likely to have achieved
successful cessation at the end of follow-up (RR=0.73 [0.57-0.93]) (Figure 4 Panel C).
Early conversion to daily smoking and rapid progression to heavy smoking mediated
genetic associations with adult smoking problems
We derived an index of adult smoking problems from a principal components analysis of 3
indicators: a) pack-years smoked by age 38 years; b) total number of Fagerstrom symptoms
across assessments; and c) the number of assessments at which study members reported
cessation failure. The adult smoking problems factor explained 78% of the variance in the 3
indicators. Individuals at higher genetic risk developed more smoking problems in
adulthood (r=0.10, p=0.012). We next tested whether this association was accounted for by
the more rapid developmental progression of smoking behavior among individuals at higher
genetic risk. 81% of this association was accounted for by the two adolescent developmental
phenotypes of early conversion to daily smoking and rapid progression to smoking≥20
cigarettes/day (Supplemental Table 4). As a further attempt to address the question of
whether preventing rapid progression from smoking initiation to heavy smoking could
mitigate genetic risks, we conducted a utopian control analysis:51 We asked whether genetic
risks continued to predict adult smoking problems in the subset of individuals who did
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initiate smoking, but who did not exhibit either of the rapid progression phenotypes (n=454).
In this subgroup, genetic risk was uncoupled from the development of smoking problems in
adulthood (r=0.05, p=0.176).
The genetic risk score captured information that could not be ascertained from a family
history of smoking behavior
The family history score and the GRS were uncorrelated (r=0.011). Both family history and
the GRS predicted study members’ smoking phenotypes (Table 1). When family history and
the GRS were both standardized and included in regression models simultaneously, GRS
and family history coefficients were unchanged and remained statistically significant, i.e.
genetic risk and family history were independent and additive predictors of smoking
phenotypes. In the mediation analyses, adjustment for family history did not change results.
Thus, the GRS contained different information about risk for developmental and mature
phenotypes of smoking behavior compared to family history.
COMMENT
Etiological research on substance abuse highlights the importance of progression from
initiation to heavy use during adolescence in the development of dependence in
adulthood.52,53 In this study, we linked the developmental progression of smoking behavior
to genetic risk. We derived a genetic risk score (GRS) from GWAS of smoking quantity.
This GRS was not related to smoking initiation. In fact, daily smokers who did not progress
to heavy use were at lower genetic risk than individuals who never smoked. Among
individuals who initiated smoking, those at higher genetic risk progressed more rapidly to
heavy smoking and nicotine dependence, were more likely to become persistent heavy
smokers and persistently nicotine dependent, and had more difficulty quitting. Critically,
high genetic risk led individuals to become persistent heavy smokers, nicotine dependent,
and unable to quit only to the extent that they progressed rapidly from smoking initiation to
heavy smoking during adolescence.
The GWAS from which we derived our measure of genetic risk were designed to discover
genetic correlates of smoking quantity. Therefore, the fact that genetic risks discovered by
these GWAS do not predict smoking initiation is not entirely unexpected. Nevertheless, that
so-called “chippers” (light but persistent smokers)54 in our cohort had below average genetic
risk is consistent with the theory that the genetic risks captured in our score influence
response to nicotine, not the propensity to initiate smoking.17,55 Thus, our result affirms the
value of using former and light smokers as a comparison group to heavy and nicotine
dependent smokers in discovery analyses targeting these risks.
Previous research has related polymorphisms in the genes included in our genetic risk score
to developmental phenotypes of smoking behavior24,26,32-35 and to mature phenotypes of
adult smoking problems.29-31,56-58 To our knowledge, ours is the first study to track the
relations of particular genetic risk variants with the development of smoking behavior from
initiation through conversion to daily smoking and progression to heavy smoking, and on to
the mature phenotypes of persistent of heavy smoking, nicotine dependence, and struggles
with cessation through mid-life. Moreover, this extended follow-up allowed us to show, for
the first time, that GWAS-identified variation in 15q25.1 and 19q13.2 influences adult
smoking problems through a pathway mediated by adolescent progression from smoking
initiation to heavy smoking. Our study is also the first to show that GWAS-identified SNPs
provide information about smoking risks that cannot be ascertained from a family history,
including information about risk for cessation failure.
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These findings should be considered in light of three limitations. First, although the Dunedin
Study sample consisted of European-descent individuals, as did the samples analyzed in the
GWAS used to develop the GRS, we cannot rule out the possibility of population
stratification. Further, replication in other populations is needed.59 Second, our analyses of
cessation were subject to censored data. The life history calendars ended at the age 38
follow-up and thus the data do not reflect relations with phenotypic events occurring after
this age. Also, self-reports of temporally remote events could be inaccurate due to forgetting
or other biases. Third, the four-decades of follow-up in the Dunedin Study coincided with
major secular events such as bans against smoking in the workplace. Comparisons of
cohorts born at different times might elucidate gene-policy interactions in smoking behavior
and speak to the generalizability of the current findings.60,61
Despite these limitations, this study has implications for etiological research and public
health. With respect to etiology, our study makes 3 contributions: First, next generation
sequencing studies and other efforts to ascertain causal variants responsible for GWAS
signals may maximize their discovery potential by focusing on samples of young people
strategically selected to reflect important developmental transitions. Such work could use
experimental designs to test hypotheses about mechanisms of genetic risk on post-initiation
phenotypes. Second, we demonstrated that a genetic risk score based on the assumption of
additive risks can be used to follow-up GWAS results in a birth cohort far smaller than the
original discovery samples. Future etiological research can use genetic risk scores to apply
GWAS results to longitudinal studies. Third, results are consistent with the hypothesis in
pediatric medicine that some adolescents, after only experimental use, are prone to quickly
become heavy users and dependent.62 This finding suggests gene-environment interaction
(GxE) analyses of smoking and nicotine dependence may profit from a focus on
environments that coincide with or immediately precede the adolescent period and influence
the propensity of high genetic risk children to initiate smoking. Smoking by peers is one
such environment.63 Tobacco control policies targeting youth may be another.64,65
Turning to public health, our research adds a genetic dimension to long-standing arguments
that early prevention could be a critical strategy in reducing cigarette consumption.66
Specifically, our findings and others’32 suggest that initiatives that disrupt the
developmental progression of smoking behavior, such as surtaxes and age restrictions on
tobacco purchases, may ameliorate some genetic risks.67 Moving beyond population-level
prevention, we showed that information about smoking risk captured in a score composed of
GWAS-identified variants was independent of information that could be derived from a
family history of smoking behavior. This novel finding suggests that genetic information
could be used to identify “high-risk” youngsters for targeted prevention.62,68 However, the
associations we detected between the genetic risk score and smoking phenotypes were small
in magnitude. Small effect sizes do not preclude public-health relevance,69 but they do
caution against the use of genetic information to evaluate risk in individuals;70 children that
our study would classify at high genetic risk are not guaranteed to become addicted if they
try smoking and, even more importantly, children we would classify at low genetic risk are
not immune to addiction. The public-health use of the current findings must be tempered
with recognition that most “risk-associated” genetic variation does not determine poor health
outcomes and, correspondingly, its absence does not guarantee protection.71,72
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genetic risk and the developmental progression of smoking behavior
In the hypothesized model, genetic risk influences the mature phenotypes of heavy smoking
persistence, nicotine dependence, and cessation failure through a pathway mediated by three
developmental phenotypes: smoking initiation, conversion to daily smoking; and
progression to heavy smoking.
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Figure 2. Smoking behavior in the Dunedin cohort
Panel A. Developmental Progression of Smoking Behavior in the Dunedin cohort. Study
members reported their smoking status during in-person assessments at ages 11 (percent
ever-smokers=7%), 13 (13%), 15 (62%), 18 (66%), 21 (70%), 26 (70%), 32 (71%), and 38
years (71%) and their daily cigarette consumption at ages 13 (percent daily smokers=1%),
15 (14%), 18 (31%), 21 (34%), 26 (35%), 32 (30%), and 38 years (20%). We assessed
nicotine dependence using the Fagerstrom Test of Nicotine Dependence (FTND),73
completed by study members at the age-21, -26, and -38 assessments. We assessed cessation
failure using study members’ reports of quit attempts and outcomes at the ages 18, 21, 26,
32, and 38 assessments. Panel B. Measurements of Developmental and Mature Smoking
Phenotypes
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Figure 3. A genetic risk score derived from GWAS of smoking quantity is associated with the
developmental progression of smoking behavior in a birth cohort of European-descent
individuals
Panel A shows that individuals at higher genetic risk progressed more rapidly from smoking
initiation to heavy smoking. Panel A graphs hazard functions for onset of heavy smoking
among individuals at low genetic risk (genetic risk Z-score=-1, green line), average genetic
risk (genetic risk Z-score=0, black line), and high genetic risk (genetic risk Z-score=1, red
line). The dashed gray line marks the cumulative hazard for individuals at average genetic
risk. The hazard function was estimated from a Cox proportional hazard model with time
since onset of ever-smoking as the exposure time and the first assessment a study member
reported smoking ≥20 cigarettes/day as the failure event. The hazard model included all
individuals who ever initiated smoking (N=627). Individuals at higher genetic risk
progressed more rapidly from smoking initiation to smoking ≥20 cigarettes/day (Hazard
Ratio=1.35 [1.14-1.58]). Panel B shows that genetic risk was highest among individuals who
progressed to heavy smoking and lowest among individuals who initiated smoking but who
did not progress to heavy smoking. The figure shows the genetic risk Z-sores (+/- 1 standard
error) for each group. “CPD” is “cigarettes per day.” A genetic risk Z-score of 0 corresponds
to the average genetic risk in the cohort. Error bars reflect standard errors of the sub-group
means.
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Figure 4. Genetic risk predicts mature phenotypes of smoking behavior
Panel A shows that among individuals who initiated smoking, those at higher genetic risk
smoked more cigarettes by age 38 years. Ever-smokers were all individuals who initiated
smoking by age 38 years (N=627). The bars of the histogram graph the percentages of the
sample carrying 1-12 risk alleles. The dots and standard-error bars reflect average lifetime
cigarette consumption (in pack-years) for ever-smokers carrying 1-3, 4, 5, 6, 7, 8, 9, 10, and
11-12 risk alleles. The regression line shows the association between the genetic risk score
and pack-years smoked by age 38 years (Pearson Correlation r=0.12, p=0.003). Panel B
shows that ever-smokers at higher genetic risk were more likely to be nicotine dependent.
The bars of the chart graph the proportion of ever-smokers at low (n=157), average (n=292),
and high (n=178) genetic risk (left side) who became nicotine dependent (≥4 Fagerstrom
symptoms) by age 38 years; and (right side) who were nicotine dependent at two or more
assessments. Panel C shows that smokers at higher genetic risk were more likely to
experience cessation failure during their 30s. The bars of the chart graph the proportions of
daily smokers at low, average, and high genetic risk (left side) who experienced relapse
following a quit attempt lasting ≥1 month; and (right side) who achieved successful
cessation (abstinence ≥1 year) through age 38 years. Percent with relapse was calculated
from cohort members who quit smoking for ≥1 month during ages 32-38 years (n= 36 for
the low genetic risk group; n= 61 for the average genetic risk group; n=34 for the high
genetic risk group). Percent with successful cessation was calculated for cohort members
who smoked daily during their 30s (n=65 for the low genetic risk group; n=120 for the
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average genetic risk group; n=77 for the high genetic risk group). In panels B and C, low
genetic risk individuals had GRSs more than 0.5 standard deviations below the cohort mean;
average genetic risk individuals had GRSs within 0.5 standard deviations of the cohort
mean; and high genetic risk individuals had GRSs more than 0.5 standard deviations above
the cohort mean. Error bars reflect standard errors.
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Table 1
Effect sizes for genetic and family history associations with developmental and clinical
phenotypes of smoking behavior
Effect sizes are for a one standard deviation increase in the predictor variable (the genetic risk score or the
family history score). Effect size measures are Pearson correlations, ‘r’; relative risks ‘RR’ from Poisson
regression models; incident rate ratios ‘IRR’ from negative binomial regression models; hazard ratios ’HR’
from Cox proportional hazard models; and beta coefficients ‘B’, from linear regression models. All models
were adjusted for sex. Effect sizes in gray text were not statistically significant at the α=0.05 level. 95%
confidence intervals for effects are included in brackets below the effect sizes. The genetic risk score and the
family history score were independent predictors of all outcomes. Effect sizes from regression models
including both the genetic risk score and the family history score were nearly identical to the effect sizes
reported in this table.
Effect Size Measure Genetic Risk Score Family History Score




Smoking Initiation (among n=880 Individuals; n=627 Who Ever Initiated Smoking)
        Ever-Smoker Status RR 0.98 [0.95-1.02] 1.12 [1.07-1.17]
        Lifetime Hazard for Smoking Initiation
HR
* 1.01 [0.94-1.09] 1.06 [0.98-1.15]
Progression from Initiation to Heavy Smoking (among n=627 Ever-Smokers)
        Early Conversion to Daily Smoking (by Age 15 Years) RR 1.24 [1.06-1.45] 1.52 [1.27-1.83]
        Rapid Progression to Smoking ≥20 Cigarettes/Day (by Age 18
Years)
RR 1.43 [1.10-1.86] 1.68 [1.26-2.24]
        Lifetime Hazard for Smoking ≥20 Cigarettes/Day
HR
* 1.35 [1.14-1.58] 1.47 [1.23-1.76]
Mature Phenotypes
Heavy Smoking Persistence (among n=627 Ever Smokers)
        Lifetime Cigarette Consumption (Pack Years) B 1.05 [0.36-1.73] 2.49 [1.80-3.19]
        Count of Assessments Smoking ≥20 Cigarettes/Day IRR 1.26 [1.07-1.49] 1.49 [1.24-1.80]
Nicotine Dependence (among n=627 Ever Smokers)
        Lifetime Hazard to Becoming Nicotine Dependent (≥4
Fagerstrom Symptoms) HR
* 1.27 [1.09-1.47] 1.53 [1.29-1.80]
        Count of Assessments with Nicotine Dependence IRR 1.22 [1.06-1.41] 1.50 [1.28-1.75]
Smoking to Cope with Stress (Ages 32-38 Years, Among n=277 Daily Smokers)
        Smoking to Cope Score B 0.22 [0.11-0.32] 0.09 [-0.06-0.24]
Cessation Failure
    Ages 18-32 years (n=405 Daily Smokers; among n=364 who Attempted Cessation)
        Risk of Cessation Failure
RR
* 1.11 [1.01-1.22] 1.11 [1.00-1.23]
    Ages 32-38 Years (n=277 Daily Smokers; n=146 Who Quit for ≥1 Month)
        Hazard of Relapse Following Quit Attempts Lasting ≥1 Month
HR
* 1.22 [1.02-1.45] 0.96 [0.79-1.17]
        Likelihood of Successful Cessation (among daily smokers) RR 0.73 [0.57-0.93] 0.94 [0.73-1.20]
*
Effect-size measures with a star were estimated from longitudinal datasets including repeated observations of individuals over time.
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